Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07807969) titled 'An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)' on Sept. 3.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Annexon, Inc.
Condition:
Geographic Atrophy
Intervention:
Drug: Vonaprument
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 30, 2026
Target Sample Size: 605
Countries of Recruitment:
United States
To know more...